Novel Antimicrobials and AMR Diagnostics 2019

Programme - Day 2

Overview of preliminary programme structure

At a glance | Day 1 | Day 2


08:00–17:00 Registration, Poster Presentations and Exhibition open
08:45–08:50 Opening Remarks
by conference organizer BIOCOM AG
08:50–10:30Plenary Session
Update and progress report with regard to AMR innovations for human and animal health

The plenary session will give a progress report on AMR innovations and financing in the therapeutics and diagnostics field. It will have a one health approach, covering human health and animal health aspects. A focus will be on developments relevant for SMEs and mid-size companies. It will address their needs and day-to-day challenges and will open the room for solutions that will be presented and discussed throughout the day.

Confirmed speakers:
• Peter Beyer, WHO (Summary of Policy Forum Day 1 & Presentation preclinical & clinical pipeline report)
• Aleks Engel, Repair Impact Fund (Update of activities & first investments), DK
• Alex van Belkum, R&D Director, bioMérieux, FR
Panel Debate: Too many cooks spoil the broth: Is the AMR field getting over-coordinated by public and private initiatives? What is really needed to drive innovation?

Additional panelists:
• Elmar Nimmesgern, Global AMR R&D Hub
• Jonathan Pearce, MRC, UK & JPI AMR
10:30–11:00 Break
11:00–12:30Parallel Sessions
Session 3
Clinical Development & Regulation

The focus of track 3 will be on the challenges which come along with clinical development of new antimicrobials thereby having a focus on trial design for non-traditional routes and the need for new guidelines, the value of clinical trial networks and measures in preclinical development that could reduce attrition in clinical phases. The session will be complemented by case studies from clinical stage SMEs & a panel debate.

Confirmed speakers:
• Helmut Kessmann, Polyphor Ltd, CH
• Florence Séjourné, Da Volterra, FR
• Seamus O'Brien, GARDP

Session 4
Market Access - US market as role model or does Europe need a specific/own way?

The session will discuss one of the major topics in the AMR community: the broken economic model. It will focus on current instruments available to incentivise AMR innovation and looks at new PUSH and PULL strategies proposed by experts. A panel will shed light on the SMEs perspective: what are their needs with regard to reimbursement and return of investment and which instrument would fit the best to support growing the community?

Confirmed speakers:
• Marie Petit, BEAM Alliance 
• Colm Leonhard, Consultant Clinical Advisor, National Institute for Health and Clinical Excellence, UK

Session 5
Surveillance – A new tool to improve R&D for drugs and diagnostics, the challenge of data integration and the role of large industry/SMEs

The session will have a special focus on how surveillance data can be used to create a more efficient, reliable and successful drug and diagnostic development process to combat antibiotic resistance in the long-term. It will present current strategies and international efforts of sharing and collecting existing data and will discuss the role of industry and SMEs within this challenge. Another aspect will cover the challenges to integrate human and animal health data and the related challenge to identify relevant diagnostic tools.

Confirmed session chair:
• Ghada Zoubiane, Wellcome Trust, UK
12:30–14:00Lunch, Exhibition and Poster Presentations
14:00–15:30Parallel Sessions and Investor Partnering
Session 6
Therapeutics (humans)

This session will focus on innovative SMEs with more traditional human therapies like small molecules or peptides to directly target resistant bacteria. The session will be jointly moderated by BEAM Alliance and CARB-X.

Confirmed speakers:
• Kevin Outterson, CARB-X, US 
• Marc Gitzinger, BioVersys AG, CH 
• Marc Lemonnier, Antabio SAS, FR
Session 7
Diagnostics (humans)

This session will focus on the relevance of diagnostics in the fight against antimicrobial resistance and provides an overview of the most recent developments in this area. Speakers from different companies will highlight new diagnostic tests or panels for either susceptibility, point-of-care or point-of-prescription testing.
Session 8
Animal Health

To address the one health approach in tackling spreading antimicrobial resistance and the growing need for alternatives to antibiotics, track 8 will present therapeutic and diagnostic innovations in animal health showcasing new antimicrobial approaches and innovative AMR diagnostics for usage in veterinary settings. The session particularly aims at providing insights into possible synergies between human and animal health experts to fight AMR.

Confirmed speaker:
• Dagmar Köhler-Repp, Ripac Labor GmbH, GER
Investor Partnering
Pre-scheduled 1-to-1 meetings (13:30–15:30)
16:00–17:30Plenary Session

Financing Session
Start-up Pitch and Investor's Talk

Traditionally, a session on early financing opportunities will close the conference. The session will be opened by 5-minutes pitches of 7 AMR therapeutic and diagnostics start-ups. The pitches will be ranked by a Jury of investors and representatives of funding initiatives from across the globe. The session will then be closed by a panel debate with representatives from private, public and corporate investors as well as by company representatives talking about their success of having raised private capital with AMR innovation in recent times.

Confirmed panelists:
• Peter Jackson, AMR Centre, UK (Moderation) 
• Emmanuelle Coutanceau, Novo Seeds, Novo Holdings, DK
• Kevin Outterson, CARB-X, US

• John Rex, CMO, F2G Ltd.

17:30–18:30Closing Reception and Poster Prize Ceremony